Citations

Clear

14 citation(s) found for "Assuncao, Thiago de".

Mutant KRAS Heterogeneity Shapes Nuclear Architecture During Pancreatic Cancer Initiation
Pollin, Gareth , Leverence, Elise, Assuncao, Thiago M. de , Iovanna, Juan, Hong, Johnny C. , Zimmermann, Michael T. , Urrutia, Raúl , Lomberk, Gwen , Mathison, Angela J , Zimmermann, Michael T , Urrutia, Raul , Lomberk, Gwen L , Mathison, Angela , Iovanna, Juan

Mayo Clinic

Epigenomes | March 10, 2026 | Volume: 10 | Issue: 1 | Pages: 19

10.3390/epigenomes10010019 | PMID 41892368 Get It

Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) arises predominantly from activating KRAS mutations, yet individual genetic variants differ markedly in signaling output and clinical impact. G12D, the most prevalent variant, strongly drives oncogenic programs, whereas G12R signals less efficiently through the AKT and ERK pathways and is associated with longer patient survival than G12D-driven PDAC. Methods: To elucidate how these differences influence early cellular transformation, we expressed a panel of KRAS mutants in non-cancerous pancreatic ductal epithelial cells as a model of early PDAC initiation and profiled transcriptional and phospho-proteomic responses. We next examined whether epigenetic differences translate into mutation-specific changes in nuclear organization using quantitative imaging of G12D- and G12R-expressing nuclei at 24 and 48 h. Results: Each variant established a unique regulatory program enriched for chromatin remodelers, histone modifiers, and nuclear structural factors, indicating that variant-specific KRAS signaling rapidly develops divergent epigenetic states. Integrated transcriptomic and phospho-proteomic analyses identified G12D and G12R as the most divergent variants. G12D induced pronounced nuclear remodeling, including increased nuclear size, irregular morphology, and reorganization of the nucleolus and spliceosome, consistent with extensive chromatin and transcriptional reprogramming. In contrast, G12R elicited a weaker response, with minimal or delayed structural changes. Conclusions: Together, these findings demonstrate that KRAS mutational context in pancreatic ductal epithelial cells shapes early transcriptional reprogramming that actively remodels nuclear architecture and nuclear sub-compartments. This work establishes nuclear structural remodeling as a structural state of KRAS-driven epigenetic dysregulation during PDAC initiation.
Discovery of a MET-driven monogenic cause of steatotic liver disease
Wagenknecht, Jessica B. , Jorge, Salomão Dória , Tian, Shulan , Luehrs, Anthony C. , Assuncao, Thiago M. de , Cao, Yang , Klee, Eric W. , Vairo, Filippo , Urrutia, Raúl , Vairo, Filippo Pinto e , Zimmermann, Michael T. , Vierkant, Robert A. , Mathison, Angela , Atwal, Paldeep S , Allen, Alina M. , Lazaridis, Konstantinos N.

Mayo Clinic

Hepatology | January 29, 2025 | Volume: 82 | Issue: 6 | Pages: 1512-1522

10.1097/hep.0000000000001249 | PMID 39879586 Get It

Background and Aims: Metabolic dysfunction–associated steatotic liver disease affects about a third of adults worldwide and is projected soon to be the leading cause of liver cirrhosis. It occurs when fat accumulates in hepatocytes and can progress to metabolic dysfunction–associated steatohepatitis, liver cirrhosis, and HCC. Metabolic dysfunction–associated steatotic liver disease pathogenesis is believed to involve a combination of genetic and environmental risk factors. Single nucleotide polymorphisms have been implicated, but non-syndromic monogenic causes are lacking. Approach and Results: We identified a novel genetic variant in a familial case of metabolic dysfunction–associated steatohepatitis and performed deep variant functional analysis, including protein modeling, dynamics, and cell-based assays to assess molecular mechanisms of dysfunction and altered cellular signaling. We analyzed exome sequencing data of 3904 individuals with steatotic liver disease (SLD) to identify additional cases and establish the link between specific gene variants and SLD diagnosis. We discovered and functionally validated the NM_000245.4:c.3505A>T; p.(Ile1169Phe) variant in the MET (mesenchymal-epithelial transition) kinase domain as a monogenic cause of SLD. Subsequently, we detected additional ultra-rare, previously uninterpreted, and likely deleterious variants in MET from screening sequencing data. Among individuals with confirmed SLD based on electronic record review, 1.1% (45/3904) had rare predicted deleterious MET variants. Eight of 45 (17.7%) individuals had predicted deleterious variants in the MET kinase domain confirmed to be functionally like the familial case variant. Conclusions: We report the first germline nonmalignant rare MET -driven disease, a monogenic form of SLD.
Writers and readers of H3K9me2 form distinct protein networks during the cell cycle that include candidates for H3K9 mimicry
Pollin, Gareth , Assuncao, Thiago M. de , Jorge, Salomão Dória , Chi, Young‐In , Charlesworth, M. Cristine , Lomberk, Gwen , Lomberk, Gwen L , Charlesworth, M. Cristine , Madden, Benjamin J. , Iovanna, Juan , Zimmermann, Michael T. , Urrutia, Raúl

Mayo Clinic

Bioscience Reports | October 2, 2023 | Volume: 43 | Issue: 10 | Pages: No page available

10.1042/bsr20231093 | PMID 37782747 Get It

Abstract Histone H3 lysine 9 methylation (H3K9me), which is written by the Euchromatic Histone Lysine Methyltransferases EHMT1 and EHMT2 and read by the heterochromatin protein 1 (HP1) chromobox (CBX) protein family, is dysregulated in many types of cancers. Approaches to inhibit regulators of this pathway are currently being evaluated for therapeutic purposes. Thus, knowledge of the complexes supporting the function of these writers and readers during the process of cell proliferation is critical for our understanding of their role in carcinogenesis. Here, we immunopurified each of these proteins and used mass spectrometry to define their associated non-histone proteins, individually and at two different phases of the cell cycle, namely G1/S and G2/M. Our findings identify novel binding proteins for these writers and readers, as well as corroborate known interactors, to show the formation of distinct protein complex networks in a cell cycle phase-specific manner. Furthermore, there is an organizational switch between cell cycle phases for interactions among specific writer–reader pairs. Through a multi-tiered bioinformatics-based approach, we reveal that many interacting proteins exhibit histone mimicry, based on an H3K9-like linear motif. Gene ontology analyses, pathway enrichment, and network reconstruction inferred that these comprehensive EHMT and CBX-associated interacting protein networks participate in various functions, including transcription, DNA repair, splicing, and membrane disassembly. Combined, our data reveals novel complexes that provide insight into key functions of cell cycle-associated epigenomic processes that are highly relevant for better understanding these chromatin-modifying proteins during cell cycle and carcinogenesis.
Induced Pluripotent Stem Cells From Subjects With Primary Sclerosing Cholangitis Develop a Senescence Phenotype Following Biliary Differentiation
Jalan‐Sakrikar, Nidhi , Assuncao, Thiago M. de , Navarro‐Corcuera, Amaia , Hamdan, Feda H. , Loarca, Lorena, Kirkeby, Lindsey A., Resch, Zachary T., O’Hara, Steven P. , Juran, Brian D., Lazaridis, Konstantinos N. , Rosen, Charles B. , Taner, Timuçin , Shah, Vijay H. , De Assuncao, Thiago M, Taner, Timucin , Shah, Vijay H , Huebert, Robert , Lazaridis, Konstantinos N , Sakrikar, Nidhi Jalan , Heimbach, Julie K. , LaRusso, Nicholas F. , Huebert, Robert C.

Mayo Clinic

Hepatology Communications | August 26, 2021 | Volume: 6 | Issue: 2 | Pages: 345-360

10.1002/hep4.1809 | PMID 34519176 Get It

Primary sclerosing cholangitis (PSC) is a chronic fibroinflammatory disease of the biliary tract characterized by cellular senescence and periportal fibrogenesis. Specific disease features that are cell intrinsic and either genetically or epigenetically mediated remain unclear due in part to a lack of appropriate, patient‐specific, in vitro models. Recently, our group developed systems to create induced pluripotent stem cell (iPSC)‐derived cholangiocytes (iDCs) and biliary epithelial organoids (cholangioids). We use these models to investigate whether PSC cholangiocytes are intrinsically predisposed to cellular senescence. Skin fibroblasts from healthy controls and subjects with PSC were reprogrammed to pluripotency, differentiated to cholangiocytes, and subsequently grown in three‐dimensional matrigel‐based culture to induce formation of cholangioids. RNA sequencing (RNA‐seq) on iDCs showed significant differences in gene expression patterns, including enrichment of pathways associated with cell cycle, senescence, and hepatic fibrosis, that correlate with PSC. These pathways also overlapped with RNA‐seq analysis on isolated cholangiocytes from subjects with PSC. Exome sequencing on the subjects with PSC revealed genetic variants of unknown significance in the genes identified in these pathways. Three‐dimensional culture revealed smaller size, lack of a central lumen, and increased cellular senescence in PSC‐derived cholangioids. Congruent with this, PSC‐derived iDCs showed increased secretion of the extracellular matrix molecule fibronectin as well as the inflammatory cytokines interleukin‐6, and chemokine (C‐C motif) ligand 2. Conditioned media (CM) from PSC‐derived iDCs more potently activated hepatic stellate cells compared to control CM. Conclusion: We demonstrated efficient generation of iDCs and cholangioids from patients with PSC that show disease‐specific features. PSC cholangiocytes are intrinsically predisposed to cellular senescence. These features are unmasked following biliary differentiation of pluripotent stem cells and have functional consequences in epithelial organoids.
Proteasomal Degradation of Enhancer of Zeste Homologue 2 in Cholangiocytes Promotes Biliary Fibrosis
Jalan‐Sakrikar, Nidhi , Assuncao, Thiago M. de , Shi, Guang , Aseem, Sayed Obaidullah , Chi, Cheng , Shah, Vijay H. , De Assuncao, Thiago M, Sakrikar, Nidhi Jalan , Shi, Guang, Huebert, Robert C.

Mayo Clinic

Hepatology | May 9, 2019 | Volume: 70 | Issue: 5 | Pages: 1674-1689

10.1002/hep.30706 | PMID 31070797 Get It

During biliary disease, cholangiocytes become activated by various pathological stimuli, including transforming growth factor β (TGF‐β). The result is an epigenetically regulated transcriptional program leading to a pro‐fibrogenic microenvironment, activation of hepatic stellate cells (HSCs), and progression of biliary fibrosis. This study evaluated how TGF‐β signaling intersects with epigenetic machinery in cholangiocytes to support fibrogenic gene transcription. We performed RNA sequencing in cholangiocytes with or without TGF‐β. Ingenuity pathway analysis identified “HSC Activation” as the highly up‐regulated pathway, including overexpression of fibronectin 1 (FN), connective tissue growth factor, and other genes. Bioinformatics identified enhancer of zeste homologue 2 (EZH2) as an epigenetic regulator of the cholangiocyte TGF‐β response. EZH2 overexpression suppressed TGF‐β‐induced FN protein in vitro, suggesting FN as a direct target of EZH2‐based repression. Chromatin immunoprecipitation assays identified an FN promoter element in which EZH2‐mediated tri‐methylation of lysine 27 on histone 3 is diminished by TGF‐β. TGF‐β also caused a 50% reduction in EZH2 protein levels. Proteasome inhibition rescued EZH2 protein and led to reduced FN production. Immunoprecipitation followed by mass spectrometry identified ubiquitin protein ligase E3 component N‐recognin 4 in complex with EZH2, which was validated by western blotting in vitro. Ubiquitin mutation studies suggested K63‐based ubiquitin linkage and chain elongation on EZH2 in response to TGF‐β. A deletion mutant of EZH2, lacking its N‐terminal domain, abrogates both TGF‐β‐stimulated EZH2 degradation and FN release. In vivo, cholangiocyte‐selective knockout of EZH2 exacerbates bile duct ligation–induced fibrosis whereas MDR2‐/‐ mice are protected from fibrosis by the proteasome inhibitor bortezomib. Conclusion: TGF‐β regulates proteasomal degradation of EZH2 through N‐terminal, K63‐linked ubiquitination in cholangiocytes and activates transcription of a fibrogenic gene program that supports biliary fibrosis.
Pharmacological targeting of the Aurora A and histone 3 lysine 9 methyltransferase pathways in pancreatic cancer.
Salmonson, Ann, Missfeldt, Mckenna, Assuncao, Thiago de, Bintz, Jennifer , Lomberk, Gwen , Lomberk, Gwen L , Mathison, Angela , Iovanna, Juan , Huebert, Robert C.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e15715-e15715

10.1200/jco.2016.34.15_suppl.e15715 Get It

Synectin promotes fibrogenesis by regulating PDGFR isoforms through distinct mechanisms
Drinane, Mary , Yaqoob, Usman , Yu, Haibin , Luo, Fanghong , Greuter, Thomas , Kostallari, Enis , Verma, Vikas , Assuncao, Thiago M. de , Kisseleva, Tatiana , Lomberk, Gwen , Gao, Yandong , Ligresti, Giovanni , Tschumperlin, Daniel J. , Revzin, Alexander , Cao, Sheng , Shah, Vijay H. , Drinane, Mary C, Arab, Juan P, Verma, Vikas K, Maiers, Jessica, De Assuncao, Thiago Milech, Urrutia, Raúl , Lomberk, Gwen L , Kostallari, Enis , Yaqoob, Usman , Arab, Juan Pablo , Maiers, Jessica L. , Simons, Michael , Mukhopadhyay, Debabrata , Brenner, David A.

Mayo Clinic

JCI Insight | December 20, 2017 | Volume: 2 | Issue: 24 | Pages: No page available

10.1172/jci.insight.92821 | PMID 29263300 Get It

The scaffold protein synectin plays a critical role in the trafficking and regulation of membrane receptor pathways. As platelet-derived growth factor receptor (PDGFR) is essential for hepatic stellate cell (HSC) activation and liver fibrosis, we sought to determine the role of synectin on the PDGFR pathway and development of liver fibrosis. Mice with deletion of synectin from HSC were found to be protected from liver fibrosis. mRNA sequencing revealed that knockdown of synectin in HSC demonstrated reductions in the fibrosis pathway of genes, including PDGFR-β. Chromatin IP assay of the PDGFR-β promoter upon synectin knockdown revealed a pattern of histone marks associated with decreased transcription, dependent on p300 histone acetyltransferase. Synectin knockdown was found to downregulate PDGFR-α protein levels, as well, but through an alternative mechanism: protection from autophagic degradation. Site-directed mutagenesis revealed that ubiquitination of specific PDGFR-α lysine residues was responsible for its autophagic degradation. Furthermore, functional studies showed decreased PDGF-dependent migration and proliferation of HSC after synectin knockdown. Finally, human cirrhotic livers demonstrated increased synectin protein levels. This work provides insight into differential transcriptional and posttranslational mechanisms of synectin regulation of PDGFRs, which are critical to fibrogenesis.
Abstract 4060: Pharmacological targeting of the Aurora A and Histone 3 lysine 9 methyltransferase pathways in pancreatic cancer induces mitotic catastrophe
Salmonson, Ann, Missfeldt, Mckenna, Assuncao, Thiago de, Bintz, Jennifer , Christensen, Trace , Kossak, Sarah, Nair, Asha, Lomberk, Gwen , Mathison, Angela , Iovanna, Juan , Huebert, Robert C. , Lomberk, Gwen L

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 4060-4060

10.1158/1538-7445.am2017-4060 Get It

Abstract By regulating gene expression networks that mediate neoplastic behavior, epigenetic protein complexes are the ultimate effectors of oncogenic pathways. This hierarchical position of epigenetic pathways within the mechanisms that regulate cancer makes them ideal candidates for therapeutic targets. The current work was designed to characterize the role of the K9H3 Histone Methyltransferase (HMT) pathway in mediating oncogenic signals downstream of Aurora Kinase A (AurkA), with the goal of designing efficient combinatorial therapies against PDAC. Affinity protein purification, combined with mass spectrometry, demonstrates that HP1γ isolated from mitotic cells interacts with AurkA and the HMTs, G9a and GLP. We also find that this complex is critical for mitotic progression and cell proliferation. Congruently, treatment of PDAC cells with individual drugs against AurkA or HP1-HMT inhibits cell growth by inducing senescence, a cytostatic response. However, the combination of these agents has a synergistic effect of reducing cell growth in both, monolayer and spheroid cultures to result in a cytotoxic effect. Confocal and electron microscopy, along with cell cycle analysis, demonstrate that the cytotoxic effect of this combination is due to induction of mitotic catastrophe, a distinct form of cell death that occurs during mitosis. Molecularly, the combination of AurkA and HP1-HMT inhibition bypasses G2/M arrest with downregulation of the Chk1-Cdc25c pathway. In vivo treatment of PDAC orthotopic xenografts with the HP1-HMT inhibitor alone demonstrated reduced PDAC growth, and increased efficacy in PDAC growth reduction was observed in combination with the AurkA inhibitor over either individual treatment. Thus, our data demonstrate a novel AurkA-HP1-HMT mitotic pathway that holds promise for potential pharmacological targeting in combinatorial therapy for this malignancy. Citation Format: Angela Mathison, Ann Salmonson, Mckenna Missfeldt, Thiago de Assuncao, Jennifer Bintz, Trace Christensen, Sarah Kossak, Asha Nair, Juan Iovanna, Robert Huebert, Gwen Lomberk. Pharmacological targeting of the Aurora A and Histone 3 lysine 9 methyltransferase pathways in pancreatic cancer induces mitotic catastrophe [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4060. doi:10.1158/1538-7445.AM2017-4060
Combined AURKA and H3K9 Methyltransferase Targeting Inhibits Cell Growth By Inducing Mitotic Catastrophe
Mathison, Angela , Salmonson, Ann, Missfeldt, Mckenna, Bintz, Jennifer , Williams, Monique , Kossak, Sarah, Nair, Asha, Assuncao, Thiago M. de , Christensen, Trace , Buttar, Navtej , Lomberk, Gwen , De Assuncao, Thiago M, Huebert, Robert, Iovanna, Juan , Huebert, Robert C. , Lomberk, Gwen L , Mathison, Angela J

Mayo Clinic

Molecular Cancer Research | April 25, 2017 | Volume: 15 | Issue: 8 | Pages: 984-997

10.1158/1541-7786.mcr-17-0063 | PMID 28442587 Get It

Abstract The current integrative pathobiologic hypothesis states that pancreatic cancer (PDAC) develops and progresses in response to an interaction between known oncogenes and downstream epigenomic regulators. Congruently, this study tests a new combinatorial therapy based on the inhibition of the Aurora kinase A (AURKA) oncogene and one of its targets, the H3K9 methylation–based epigenetic pathway. This therapeutic combination is effective at inhibiting the in vitro growth of PDAC cells both, in monolayer culture systems, and in three-dimensional spheroids and organoids. The combination also reduces the growth of PDAC xenografts in vivo. Mechanistically, it was found that inhibiting methyltransferases of the H3K9 pathway in cells, which are arrested in G2–M after targeting AURKA, decreases H3K9 methylation at centromeres, induces mitotic aberrations, triggers an aberrant mitotic check point response, and ultimately leads to mitotic catastrophe. Combined, these data describe for the first time a hypothesis-driven design of an efficient combinatorial treatment that targets a dual oncogenic–epigenomic pathway to inhibit PDAC cell growth via a cytotoxic mechanism that involves perturbation of normal mitotic progression to end in mitotic catastrophe. Therefore, this new knowledge has significant mechanistic value as it relates to the development of new therapies as well as biomedical relevance. Implications: These results outline a model for the combined inhibition of a genetic-to-epigenetic pathway to inhibit cell growth and suggest an important and provocative consideration for harnessing the capacity of cell-cycle inhibitors to enhance the future use of epigenetic inhibitors. Mol Cancer Res; 15(8); 984–97. ©2017 AACR.
Regenerative Medicine and the Biliary Tree
Assuncao, Thiago de, Jalan‐Sakrikar, Nidhi , De Assuncao, Thiago M, Huebert, Robert C. , Sakrikar, Nidhi Jalan

Mayo Clinic

Seminars in Liver Disease | February 15, 2017 | Volume: 37 | Issue: 01 | Pages: 017-027

10.1055/s-0036-1597818 | PMID 28201845 Get It